Table 3 Extrarenal manifestations at baseline and during follow-up
Extrarenal manifestations | At baseline, pt no (%) | Pt no with baseline symptom resolution; Median months to symptom resolution (range) | New episodes, pt no (%) |
|---|---|---|---|
General symptoms | 18 (54) | 18/18; 1 (1-2) | 8 (24) |
Rash | 15 (45) | 15/15; 2 (1-15) | 9 (27) |
Oral ulcers | 4 (12) | 4/4; 1.5 (1-5) | 5 (15) |
Arthralgias/arthritis | 13 (39) | 12/13; 1 (1-5) | 10 (30) |
Alopecia | 4 (12) | 4/4; 1.5 (1-2) | 2 (6) |
Myalgias | 4 (12) | 4/4; 1 (1-2) | 2 (6) |
Serositis | 8 (24) | 8/8; 1 (1-8) | 2 (6) |
Pneumonitis | 2 (6) | 2/2; 1.5 (1-2) | 1 (3) |
Thrombosis | 2 (9) [1 PE, 2 DVTs] | 2/2 | 0 |
CNS | 2 (6) [brain infarcts] | 1 both pts | 1 (3) [seizures] |
Myositis | 0 | Â | 1 (3) |
Hepatosplenomegaly | 5 (15) | 5/5 | 1 (3) |
Anemia (Hb < 12 g/dl for female and < 13.5 g/dl for male) | 15 (45) | 10/15; 4 (1-18) | 5 (15) |
   Hemolytic anemia | 8 (24) |  | 2 (6) |
   Aplastic anemia | 1 (3) |  | 1 (3) |
Leucopenia (<3.500/mm3) | 13 (39) | 11/13; 1 (1-14) | 8 (24) |
Thrombocytopenia (<100.000/mm3) | 0 | Â | 0 |
Increased liver enzymes | 5 (15) | 5/5; 1 (1-2) | 2 (6) |